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A B S T R A C T
The aim of this study was to determine the predictors of mortality among patients infected with
Crimean-Congo haemorrhagic fever (CCHF) virus. Among patients with acute febrile syndrome,
characterised by malaise, bleeding, leukopenia and thrombocytopenia, who were admitted to hospital
during the spring and summer of 2002–2004, 54 had positive IgM and ⁄ or PCR results for CCHF virus in
blood or tissue. The overall case fatality rate was 7.4%. Among the fatalities, haematemesis (p 0.009),
melaena (p 0.001) and somnolence (p 0.022) were more common, the median platelet count was
significantly lower (10 600 ⁄mL vs. 20 000 ⁄mL; p 0.038), the mean prothrombin time (27 s vs. 16 s;
p 0.002) and mean activated partial thromboplastin time (73 s vs. 44 s; p < 0.001) were longer, and the
mean alanine transferase (ALT) level (1125 vs. 331; p < 0.001), the mean aspartate transferase (AST) level
(3118 vs. 913; p 0.004) and the mean fibrinogen level (119 vs. 340; p 0.012) were higher. Serum IgM and
IgG against CCHF virus was detected in 25% and 0%, respectively, of fatal cases, compared with 94%
and 62%, respectively, of cases with favourable outcomes. Oral ribavirin was prescribed to 22 (41%)
patients. Of the four fatal cases, it was the intention to prescribe ribavirin to three patients, but this was
not possible because of haematemesis and melaena. Higher levels of AST (‡ 700 U ⁄L) and ALT
(‡ 900 U ⁄L) are suggested for use as severity criteria. Oral ribavirin was not effective for patients with
haematemesis, and intravenous ribavirin is necessary for treatment of CCHF.
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I N T R O D U C T I O N
Crimean-Congo haemorrhagic fever (CCHF) is a
fatal viral infection described in parts of Africa,
Asia, Eastern Europe and the Middle East [1]. The
virus belongs to the genus Nairovirus in the
Bunyaviridae family, and causes severe disease
in humans, with a reported mortality rate of 15–
30% [2]. Humans become infected through the
bites of ticks, by contact with a patient with CCHF
during the acute phase of infection, or by contact
with blood or tissues from viraemic livestock [3].
Cases infected with CCHF virus (CCHFV) were
first reported in Turkey in 2002 [4–6], although
epidemics were reported before 2003 in neigh-
bouring countries. CCHFV infection is an import-
ant public health issue in Turkey because of its
high case fatality rate. Since 2002, 399 cases of
CCHF have been reported to the Ministry of
Health of Turkey, and 19 (4.7%) of these cases
died. The present study analysed the risk-factors
of 54 CCHF patients, based on epidemiological,
clinical and laboratory findings. Based on this
analysis, the predictors of fatality criteria, defined
previously by Swanepoel et al. [7] in 1989, were
reassessed.
M A T E R I A L S A N D M E T H O D S
Patients with acute febrile syndrome, characterised by malaise,
bleeding, leukopenia and thrombocytopenia, during the spring
and summer of 2002, 2003 and 2004 were admitted to the
Infectious Diseases and Clinical Microbiology Clinic of Ankara
Numune Education and Research Hospital. Patients with
positive IgM and ⁄ or PCR results for CCHFV in blood or
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tissue were included in the study. Recent or current CCHFV
infection was confirmed by demonstrating seroconversion, or
at least a four-fold increase in antibody titre in paired serum
samples, or IgM antibodies with ELISA in a single sample [8].
ELISA methods are quite specific and much more sensitive
than immunofluorescence and neutralisation tests [9]. RT-PCR
is the method of choice for rapid laboratory diagnosis of
CCHFV infection [10].
The presence of antibodies to Leptospira, Lyme disease,
Salmonella, rickettsiae, Brucella, Coxiella burnetii, Toxoplasma,
rubella virus, cytomegalovirus, herpes virus and hepatitis A,
B and C viruses was investigated by serology. Acute and
convalescent sera from all the acute cases were sent to the
Refik Saydam Hygiene Center of Ankara, Turkey for ELISA
and PCR tests [8,10]. Laboratory parameters were measured
on a daily basis following hospital admission.
The patients were given erythrocytes, fresh frozen plasma
and total blood preparations, depending on the state of their
haemostasis. The patient characteristics were assessed accord-
ing to the 90% fatality outcome criteria described by Swane-
poel et al. [7]. According to these criteria, patients were defined
as ‘severe’ when they had white blood cell (WBC) counts
‡ 10 000 ⁄mm3, platelet counts (PLT) £ 20 000 ⁄mm3, aspartate
transferase (AST) levels ‡ 200 U ⁄L, alanine transferase (ALT)
levels ‡ 150 U ⁄L, activated partial thromboplastin times
(aPTT) ‡ 60 s, or fibrinogen levels £ 110 mg ⁄dL during the
first 5 days of illness. Various threshold levels were investi-
gated with the aim of achieving higher sensitivity, specificity,
positive and negative predictive values.
Mean comparisons for continuous variables were
performed using independent group t-tests. Proportion
comparisons for categorical variables were performed using
chi-square tests, with Fisher’s exact test being used when data
were sparse. A multivariate analysis was performed for the
prediction of fatality. Physical findings, haematemesis, melae-
na, somnolence, and the laboratory tests (AST, ALT, PLT, WBC
count, lactate dehydrogenase (LDH), creatine phosphokinase
(CPK), prothrombin (PT), aPTT and fibrinogen) were included
in the model as independent variables. Significance was set at
p < 0.05 using two-sided comparisons. The STATA v.8.0
software package (Stata Corp., College Station, TX, USA) was
used for the analyses.
Results of diagnostic tests were not available for up to
4 weeks; therefore, all ribavirin therapy was initiated before
laboratory evidence of CCHF infection. Oral ribavirin was
administered, within a mean 5.5 days following the onset of
symptoms, at the dosage recommended by the WHO (4 g four
times daily for 4 days; 2.4 g four times daily for 6 days) [11].
The intravenous form of ribavirin was not available in Turkey
at this time. Written consent was obtained from the patients or
their family members.
R E S U L T S
Fifty-four patients were admitted from various
regions of north-eastern Anatolia and the southern
parts of the Black Sea region; all of these patients
were involved in animal husbandry. Four (7.4%)
cases were fatal with massive haemorrhage. The
age, gender and number of days from the appear-
ance of symptoms to admission were similar
between favourable and fatal cases (p > 0.05).
Fever lasted for an average 4.3 (± 2.5) days. Among
the clinical findings, haematemesis (p 0.009), mel-
aena (p 0.001) and somnolence (p 0.022) were more
common among fatal cases (Table 1).
Forty-eight (89%) of the 54 patients were IgM-
positive, 31 (57%) were IgG-positive during the
acute or convalescent phase, and 22 (41%)
patients were PCR-positive (Table 2).
All the patients had leukopenia, thrombocy-
topenia, and elevated AST, ALT, LDH and CPK
levels (Table 3). On admission, 31 patients had
thrombocytopenia of £ 20 000 ⁄mm3, 45 patients
had AST levels ‡ 200 U ⁄L, 40 patients had ALT
levels ‡ 150 U ⁄L, 16 patients had aPTT of > 60 s.
The fibrinogen level of one patient was
£ 110 mg ⁄dL. None of the patients had leukocy-
tosis, with the exception of one fatal case whose
leukocyte count increased to 12 000 ⁄mm3 on the
final day (day 10 since the onset of disease).
Among the fatal cases, the median PLT was
significantly lower (10 600 ⁄mL vs. 20 000 ⁄mL;
p 0.038), the mean PT (27 s vs. 16 s; p 0.002) and
Table 1. Demographic characteristics of 54 patients with
Crimean-Congo haemorrhagic fever
Favourable cases
n = 50 (%)
Fatal cases
n = 4 (%) p
Number of females 26 (52) 2 (50) 0.939
Mean age (SD), years 43 (18) 54 (11) 0.280
Days from symptoms to admission 6 4 0.074
Symptoms
Nausea-vomiting 41 (82) 4 (100) 0.471
Myalgia 31 (62) 4 (100) 0.285
Fever 38 (76) 4 (100) 0.576
Headache 35 (70) 3 (75) 0.684
Physical findings
Fever (Temperature > 38 C) 21 (42) 2 (50) 0.755
Bleeding
Haematemesis 13 (26) 4 (100) 0.009
Melaena 7 (14) 4 (100) 0.001
Epistaxis 20 (40) 3 (75) 0.301
Haemoptysis 4 (8) 1 (25) 0.341
Haematuria 8 (16) 0 (0) 0.509
Maculopapular rash 15 (30) 1 (25) 0.640
Conjunctival injection 21 (42) 1 (25) 0.638
Somnolence 17 (34) 4 (100) 0.022
Jaundice 5 (10) 1 (33) 0.330
Diarrhoea 17 (34) 2 (50) 0.607
Hepatomegaly 17 (35) 0 (0) 0.293
SD, standard deviation.
Table 2. Serology and PCR results for 54 patients with
Crimean-Congo haemorrhagic fever
Favourable cases n = 50 (%) Fatal cases n = 4
IgM-positive 47 (94) 1 (25)
IgG-positive 31 (62) 0 (0)
PCR-positive 19 (48) 3 (75)
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mean aPTT were longer (73 s vs. 44 s; p < 0.001),
the mean ALT (1125 vs. 331; p < 0.001) and the
mean AST (3118 vs. 913; p 0.004) were higher, and
the mean fibrinogen level was lower (119 vs. 340;
p 0.012) (Table 3).
The components of severity criteria defined by
Swanepoel et al. [7] were reassessed (Table 4).
Higher AST levels (‡ 700 U ⁄L instead of
‡ 200 U ⁄L) predicted fatality with greater sensi-
tivity, specificity, positive and negative predictive
values. Higher ALT levels (‡ 900 U ⁄L instead of
150 U ⁄L) increased the test performance, with the
exception of positive predictive value (Table 5).
The AST ⁄ALT ratio was higher among severe
cases than among mild-moderate cases for the
first 3 days following admission (p 0.022, 0.003
and 0.047, respectively). In multivariate analysis,
an increased ALT was associated with a fatal
outcome (OR 1.003; 95% CI 1.001–1.005; p 0.007).
LDH and CPK levels among severe cases were
higher than among mild-moderate cases,
although this was not statistically significant
(p > 0.05). Laboratory tests, including complete
blood count, and biochemical tests returned to
normal levels within 5–9 days.
Oral ribavirin was prescribed for 22 (41%) of 45
severe cases. In three of the four fatal cases, it was
the intention to prescribe oral ribavirin, but these
patients had haematemesis and melaena, and
their length of stay in the clinic was limited to 12,
36 and 48 h, respectively. Fatalities received
significantly more fresh frozen plasma (p 0.001)
and thrombocyte suspensions (p < 0.001) than
patients with favourable outcomes. No adverse
events related to ribavirin therapy were noted.
D I S C U S S I O N
CCHFV infection causes a fatal haemorrhagic
syndrome, which is a leading threat to public
health in endemic countries. Ribavirin is the drug
of choice as an antiviral agent for infected patients
[7,12]. However, use of ribavirin remains uncom-
mon for several reasons. First, ribavirin use has
not been tested in randomised clinical trials, since
ethical constraints do not allow such a study
design, although its effectiveness has been des-
cribed in observational studies [4,11,13]. Second, a
decision concerning which CCHFV-infected pa-
tients should be given ribavirin may be difficult.
Since severe cases need to be treated [4], categor-
isation of the patients according to the severity of
the infection is an essential first step in deciding
whether to initiate antiviral therapy [4].
The severity criteria defined by Swanepoel et al.
[7] did not fit perfectly to the patients in the
present study. In particular, AST and ALT levels
were found to be higher among fatal cases in the
present study, and higher threshold values for
Table 3. Laboratory findings for 54
patients with Crimean-Congo haem-
orrhagic fever
Favourable cases
Mean (min–max) n = 50
Fatal cases
Mean (min–max) n = 4 p
Longest prothrombin time, s 16 (10–42) 27 (18–33) 0.002
Longest activated partial thromboplastin time, s 44 (25–74) 73 (55–92) < 0.001
Lowest platelet count, platelets ⁄mm3 27 000 (3500–108 000) 11 000 (6000–15 000) 0.038
Lowest WBC, WBCs ⁄mm3 1880 (150–13 000) 1800 (1200–3000) 0.595
Highest alanine transferase level, U ⁄L 331 (38–1443) 1125 (219–1785) < 0.001
Highest aspartate transferase level, U ⁄L 913 (65–7150) 3200 (773–7700) 0.004
Highest lactic dehydrogenase level, U ⁄L 2545 (283–26 000) 4019 (1980–9480) 0.478
Highest creatinine phosphokinase level, U ⁄L 1277 (10–21 189) 1823 (1388–2164) 0.736
Lowest fibrinogen level 340 (165–780) 119 (86–140) 0.012
WBC, white blood cell count.







Increased WBC count ‡ 10 000 ⁄mm3 Yes No 0.595
Decreased platelet count Yes Yes 0.038
Elevated aspartate transferase level Yes Yes 0.004
Elevated alanine transferase level Yes Yes < 0.001
Prolonged activated partial
thromboplastin time
Yes Yes < 0.001
Prolonged thromboplastin time No Yes 0.002
Decreased fibrinogen £ 110 mg ⁄dL Yes Yes 0.012
Melaena No Yes 0.001
Haematemesis No Yes 0.009
Somnolence No Yes 0.022
Table 5. Aspartate transferase (AST) and alanine transf-










‡ 200 U ⁄L, Swanepoel et al. [7] 9 100 100 18
‡ 700 U ⁄L, alternative 16 100 100 58
ALT
‡ 150 U ⁄L, Swanepoel et al. [7] 10 100 100 28
‡ 900 U ⁄L, alternative 43 98 75 92
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defining severity are suggested (Table 5). Leuko-
cytosis was one of the criteria described by
Swanepoel et al. [7], but was observed only in
one patient, who died on day 8 following admis-
sion. Further observations with larger numbers of
patients are necessary to clarify this discrepancy.
In contrast, an aPTT of > 60 s was found to be
compatible with the observations in the present
study. Since the mean time for hospital admission
was 5 days among patients in the present study,
measurement ‘on admission’, instead of for the
first 5 days of illness, was practical and appro-
priate.
In a separate study, a high AST ⁄ALT ratio was
suggested as a prognostic factor for severity
among cases of CCHF, and the same parameter
was documented as a prognostic factor of fatality
[4]. In multivariate analysis, an increase in ALT
was associated with fatality (OR 1.003; 95% CI
1.001–1.005; p 0.007). An increase in ALT as the
disease progresses could be an indicator of liver
failure.
No serum IgM or IgG was detected for three of
the fatal cases, although the virus was detected by
PCR (Table 2). The absence of a significant anti-
body response in fatalities has been reported
previously [7]. Twenty-one patients (including all
the fatal cases) became stuporous, despite vigor-
ous supportive therapy, as reported previously in
another study from Turkey [6]. However, in
contrast to Swanepoel et al. [7], no renal failure
was observed.
There was an intention to treat three of the four
fatal cases with oral ribavirin (there is no paren-
teral form of ribavarin available currently in
Turkey). All the fatal cases had haematemesis
and melaena, and, except for one patient, stayed
at the clinic for only 12, 36 and 48 h, respectively.
The bleeding sites and the limited total stay
period hampered the effectiveness of the drug.
Evaluation studies for ribavarin should take into
account the severity of the patients, the period
from the onset of disease, gastrointestinal symp-
toms such as haematemesis, and the duration of
treatment. No complications following use of
ribavirin were noted.
In conclusion, higher AST (‡ 700 U ⁄L) and
ALT (‡ 900 U ⁄L) levels are suggested for inclu-
sion in a revision of the severity criteria for CCHF.
Oral ribavirin is not effective for patients with
haematemesis, and intravenous ribavirin is neces-
sary for the treatment of CCHFV infection.
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